Is Werewolf Therapeutics, Inc. (HOWL) Stock Halal or Haram?

Werewolf Therapeutics, Inc. (HOWL) - Not Halal (Non-Compliant)

Werewolf Therapeutics, Inc. (HOWL) is classified as Not Halal (Non-Compliant) according to AAOIFI Shariah screening standards. This assessment is based on business activity screening and financial ratio analysis using the AAOIFI methodology.

Business Activity Screen

Sector: Healthcare
Industry: Biotechnology
Result: Pass
Reason: The sector "Healthcare" and industry "Biotechnology" are not in the excluded categories.

Financial Ratios

Debt Ratio: Value: 0.0% | Threshold: 30% | Result: Pass
Cash & Interest-bearing Securities Ratio: Value: 71.4% | Threshold: 30% | Result: Fail
Non-Permissible Income Ratio: Value: 226.4% | Threshold: 5% | Result: Fail

Dividend Purification

Purification percentage: 100.00%.Based on the company's financial statements, approximately 100.00% of dividend income should be donated to charity for purification. This is derived from identified interest income (226.43% of total income). Some scholars may differ on the exact calculation method.

About Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Business Activity

Pass

HealthcareBiotechnology

The sector "Healthcare" and industry "Biotechnology" are not in the excluded categories.

Business-activity data: SEC filings. How coverage works

Financial Ratios

Fail

Debt Ratio0.0% / 30%

Cash & Interest-bearing Securities Ratio71.4% / 30%

Non-Permissible Income Ratio226.4% / 5%

Denominator: Market Capitalization

Dividend Purification

100.00%

Based on the company's financial statements, approximately 100.00% of dividend income should be donated to charity for purification. This is derived from identified interest income (226.43% of total income). Some scholars may differ on the exact calculation method.

Uses quarterly data

About Werewolf Therapeutics, Inc.

United StatesNASDAQHealthcare

Screened using AAOIFI Standard No. 21 on October 20, 2026. Financial ratios compared against market capitalization. Different methodologies may produce different results. Learn how we screen.

Screened using AAOIFI Shariah Standard No. 21 (3 ratios). Debt and interest-bearing deposits must each be under 30% of market capitalization, and non-permissible income under 5% of total income. This screening is for educational purposes only and does not constitute a fatwa or religious ruling. Results are based on publicly available financial data and automated analysis. Users should consult qualified Islamic scholars and financial advisors for personal investment decisions. Financial data may be delayed or incomplete. Past compliance does not guarantee future status.

Verdict history

Free with an account.

No verdict changes recorded since first screened on Aug 21, 2026. We started recording changes on Oct 19, 2026.

Dates are when Mizaan recorded the change. Tracked and watched stocks are re-checked weekly; other stocks are re-screened on demand.

Get More on the Mizaan App

Live charts, market cap, financials, AI business analysis, portfolio tracking, and compliance alerts — all on your phone.

Frequently Asked Questions

Screen Another Stock

Check if any stock or ETF is Shariah-compliant

View Portfolio

Monitor compliance across all your holdings

Screening

What Makes a Stock Halal?

Understand the business activity and financial ratio criteria used to screen stocks for Shariah compliance.

Purification

Dividend Purification Explained

Learn how to calculate and donate the non-permissible portion of your dividend income.

Frequently Asked Questions

Is Werewolf Therapeutics, Inc. (HOWL) stock halal to invest in?

According to AAOIFI Shariah screening standards, Werewolf Therapeutics, Inc. (HOWL) is currently classified as Not Halal (Non-Compliant). This is based on both business activity and financial ratio screening.

Does Werewolf Therapeutics, Inc. have any interest income?

Werewolf Therapeutics, Inc.'s interest income ratio is 71.4% of total revenue. AAOIFI standards require this to be below 30%.

What guidelines are used to determine if HOWL stock is Shariah-compliant?

HOWL is screened using AAOIFI Standard No. 21, which involves two checks: business activity screening (ensuring the company's core business is permissible in Islam) and financial ratio screening (checking debt, interest income, and cash ratios against defined thresholds). AAOIFI is the most widely recognized standard for Islamic finance.

How often is Werewolf Therapeutics, Inc. stock reviewed for Shariah compliance?

Werewolf Therapeutics, Inc.'s compliance status is reviewed whenever new financial data becomes available, typically after quarterly or annual earnings reports. Market cap changes can also affect financial ratio screening results. Mizaan refreshes screening data periodically to reflect the latest filings.

How can I stay updated on Werewolf Therapeutics, Inc.'s compliance status?

You can save HOWL to your Mizaan portfolio to track its compliance status over time. Mizaan will update the screening whenever new financial data is available, so you always have the latest result.

Are dividends from Werewolf Therapeutics, Inc. stock considered halal?

Dividends from Werewolf Therapeutics, Inc. require purification. Approximately 100.00% of dividend income should be donated to charity to cleanse earnings from non-permissible sources such as interest income.

Do I need to pay Zakat on my Werewolf Therapeutics, Inc. shares?

Yes, Zakat is generally due on stock holdings. The calculation depends on your school of thought (madhab) and whether you hold shares for trading or long-term investment. Use Mizaan's Zakat calculator to compute your obligation based on your specific madhab and holding intent.

Salaam

Werewolf Therapeutics, Inc.

Business Activity

Financial Ratios

Dividend Purification

About Werewolf Therapeutics, Inc.

Verdict history

Get More on the Mizaan App

Frequently Asked Questions

Related Stocks

Screen Another Stock

View Portfolio

Related Articles

What Makes a Stock Halal?

Dividend Purification Explained

Frequently Asked Questions